Compare ABCL & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABCL | PAHC |
|---|---|---|
| Founded | 2012 | 1946 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2020 | 2014 |
| Metric | ABCL | PAHC |
|---|---|---|
| Price | $5.63 | $32.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 4 |
| Target Price | $8.40 | ★ $41.25 |
| AVG Volume (30 Days) | ★ 8.2M | 406.7K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.91% |
| EPS Growth | 10.91 | ★ 1883.33 |
| EPS | N/A | ★ 1.90 |
| Revenue | $75,128,000.00 | ★ $833,350,000.00 |
| Revenue This Year | N/A | $17.03 |
| Revenue Next Year | $21.85 | $3.82 |
| P/E Ratio | ★ N/A | $17.07 |
| Revenue Growth | ★ 160.56 | 4.12 |
| 52 Week Low | $2.53 | $22.85 |
| 52 Week High | $6.79 | $60.08 |
| Indicator | ABCL | PAHC |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 36.35 |
| Support Level | $5.34 | N/A |
| Resistance Level | $5.63 | $34.98 |
| Average True Range (ATR) | 0.56 | 1.55 |
| MACD | 0.05 | 0.56 |
| Stochastic Oscillator | 56.84 | 60.01 |
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.